NEW YORK, August 11, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Actinium Pharmaceuticals Inc. (AMEX: ATNM),
Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), BioDelivery Sciences
International Inc. (NASDAQ: BDSI), iBio Inc. (AMEX: IBIO), and Lion
Biotechnologies Inc. (NASDAQ: LBIO). Free research report on
Actinium Pharma can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=ATNM On
Monday, August 10, 2015, the NASDAQ
Composite ended at 5,101.80, up 1.15%, the Dow Jones Industrial
Average advanced 1.39%, to finish the day at 17,615.17, and the
S&P 500 closed at 2,104.18, up 1.28%. The gains were broad
based as all the sectors ended the session in positive. Register
for your complimentary reports at the links given below.
Actinium Pharmaceuticals Inc.'s stock surged 8.59%, to close the
day at $2.15. The stock recorded a
trading volume of 5.67 million shares, much above its three months
average volume of 1.28 million shares. Over the last one month and
over the past three months, Actinium Pharmaceuticals Inc.'s shares
have declined 10.79% and 19.48%, respectively. Furthermore, the
stock has plummeted 63.50% since the start of this year. The
company's shares are trading 15.33% below their 50-day moving
average. Additionally, Actinium Pharmaceuticals Inc. has a Relative
Strength Index (RSI) of 47.07. Sign up and read the free notes on
ATNM at:
https://www.EquityResearchInstitute.com/reports?keyword=ATNM
On Monday, shares in Anthera Pharmaceuticals Inc. recorded a
trading volume of 0.70 million shares, lower than their three
months average volume of 1.26 million shares. The stock ended the
day 2.51% higher at $9.80. Anthera
Pharmaceuticals Inc.'s stock has rallied 17.72% in the last one
month, 118.75% in the previous three months and 520.25% on YTD
basis. The stock is trading above its 50-day and 200-day moving
averages by 10.90% and 108.08%, respectively. Furthermore, shares
of Anthera Pharmaceuticals Inc. have an RSI of 49.78. The
complimentary notes on ANTH can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=ANTH
BioDelivery Sciences International Inc.'s stock gained 1.29%, to
close Monday's session at $7.05. The
stock recorded a trading volume of 2.18 million shares, above its
three months average volume of 1.25 million shares. Over the last
one month and the previous three months, BioDelivery Sciences
International Inc.'s shares have declined 18.40% and 7.72%,
respectively. Additionally, the stock has lost 41.35% since the
start of this year. The stock is trading 15.29% and 39.50% below
its 50-day and 200-day moving averages, respectively. Furthermore,
BioDelivery Sciences International Inc.'s stock has an RSI of
33.68. Register for free on Equity Research Institute and access
the latest research on BDSI at:
https://www.EquityResearchInstitute.com/reports?keyword=BDSI
iBio Inc.'s stock finished Monday's session 3.36% lower at
$0.62. A total of 0.69 million shares
were traded, which was close to its three months average volume of
0.70 million shares. Over the last one month and the previous three
months, iBio Inc.'s shares have plummeted 28.08%, each.
Additionally, the stock has lost 9.71% since the beginning of 2015.
The company's shares are trading below their 50-day and 200-day
moving averages by 28.19% and 26.54%, respectively. Further, iBio
Inc.'s stock has an RSI of 30.79. The complete research on IBIO is
available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=IBIO
On Monday, shares in Lion Biotechnologies Inc. ended the session
0.41% lower at $7.37. The stock
reported a trading volume of 0.27 million shares, below its three
months average volume of 0.69 million shares. Lion Biotechnologies
Inc.'s shares have lost 19.19% in the last one month, 31.25% in the
previous three months and 6.35% on YTD basis. The stock is trading
22.94% below its 50-day moving average and 19.56% below its 200-day
moving average. Moreover, shares of Lion Biotechnologies Inc. have
an RSI of 29.99. Free in-depth research on LBIO is available
at:
https://www.EquityResearchInstitute.com/reports?keyword=LBIO
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com